吴玉敏

副研究员，研究生导师

2017年获江苏大学博士学位；2021年至2024年在www.优德88.cpm 从事博士后研究工作。2024年加入www.优德88.cpm 功能纳米与软物质研究院，被聘为副研究员。

研究领域：肿瘤及炎症免疫，合成生物学，基因编辑

主要成果和贡献：

致力于肿瘤免疫领域的机制和治疗相关的研究，设计并开发调控肿瘤免疫微环境，促进免疫应答的生物材料；主要集中于利用基因工程化的细菌调控肿瘤和炎症免疫微环境的研究。已开发多种具有调控肿瘤免疫微环境，杀伤肿瘤的基因工程细菌。以第一作者或者通讯作者在 Nature Communications、ACS Nano、Biomaterials等国际知名学术期刊上发表论文10余篇。主持国家自然科学基金青年科学基金、中国博士后基金面上项目、和江苏省博士后科研项目等项目。

个人荣誉 :

江苏省卓越博士后计划

代表性论文：

[1]. WuY, Liu B, Yan Y, Chen M, Zhu Y, Liu N, Dong Z, Feng L*, Liu Z*, Thermal-responsive activation of tumor-homing engineered bacteria to trigger robust antitumor immunity post ablation therapy.NatureCommunications (InPress).

[2]. Liu B, Wang K, Li Q, Xiao Z, Chen Z, Zhang Y, Wu Y, Xu Y,Wu Y*,Liu Z*. Engineered VNP20009 expressing IL-15&15Rα augments anti-tumor immunity for bladder cancer treatment.Biomaterials. 2024Nov 6; 315: 122951.

[3]. Ge L, Guo H, Zhou W, Shi W, Yue J,Wu Y*. Manganese-mediated potentiation of antitumor immune responses by enhancing KLRG1+ Macrophage function.Int Immunopharmacol. 2024Nov 15;141: 112951.

[4] Wu Y, Li Q, Yan Y, Hao Y, Wang C, Liu B, Zhu Y, Liu Z*, Feng L*. Gel-mediated recruitment of conventional type 1 dendritic cells potentiates the therapeutic effects of radiotherapy.Biomaterials. 2024Mar; 305: 122470.

[5]. Yue J, Guo H, Yang X, Xu P, Ma J, Shi W*,Wu Y*. Combination of IL-33 with PD-1 blockade augment mILC2-mediated anti-tumor immunity.Cancer Immunol Immunother.2024Mar 2;73(4):65.

[6]. Wu Y, Wang C, Yan Y, Hao Y, Liu B, Dong Z, Chen M, Zhu Y, Liu N, Feng L*, Liu Z*. Efferocytosis Nanoinhibitors to Promote Secondary Necrosis and Potentiate the Immunogenicity of Conventional Cancer Therapies for ImprovedTherapeuticBenefits.ACS Nano. 2023Sep 26;17(18):18089-18102.

[7]. Yue J, Guo H, Xu P, Ma J,Wu Y*. Activation of the GPR35 on ILC2 drives immunosuppression to promote lung cancer progression.Am J Cancer Res. 2023Jun 15;13(6):2426-2438.

[8]. Wu Y, Feng L*. Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy.Expert Opin Drug Deliv. 2023Mar;20(3):323-333.

[9]. Wu Y, Guo H, Yue J*, Xu P*. Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients.J Immunol Res. 2022Nov 25;2022: 9101912.

[10]. Wu Y, Shi W, Wang H, Yue J, Mao Y, Zhou W, Kong X, Guo Q, Zhang L, Xu P, Wang Y*. Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+T Response.Int J Nanomedicine. 2020Dec 3; 15: 9745-9758.

联系方式：ymwu@suda.edu.cn